For Humanity.
Saving Lives Through the Power of Early Cancer Detection

President of Tencent Healthcare, WHO (World Health Organization) Digital Health Technical Advisory Group Expert, Honorary Associate Professor, School of Public Health, The University of Hong Kong

Alex's personal mission is to support the under-privileged, the under-served and make this world a more equitable place.

Alex is currently leading Tencent Healthcare to support healthcare industry’s digital innovation and transformation. Tencent Healthcare currently connects and smoothens the process of accessing online and offline healthcare services for individuals on Tencent Healthcare mini-program, and also provides AI and cloud solutions to health agencies, hospitals, medical institutions, and pharmaceutical companies.

Alex serves on the WHO Digital Health Technical Advisory Group and Honorary Associate Professor at University of Hong Kong. Before joining Tencent, Alex was the deputy director for Health Innovation and Partnership at the Bill & Melinda Gates Foundation and Associate Partner at McKinsey & Company.

Alex is a trained physician from New Zealand where he served as the chief resident at Middlemore Hospital in Auckland. He received his medical qualifications from University of Auckland, a Master of Public Health from Harvard and Postgraduate Diploma in Health Informatics from University of Otago.

Professor Allen Chan is the Chair Professor of Chemical Pathology and the Chief of Service for the clinical service of the Department of Chemical Pathology of The Chinese University of Hong Kong (CUHK). He received his undergraduate medical training from the University of Hong Kong and started his PhD training in the Department of Chemical Pathology at CUHK in 2001 under the supervision of Professor Dennis Lo.

His main research interest is developing new diagnostic approaches based on circulating DNA analysis. The applications of his inventions cover noninvasive prenatal testing, cancer diagnostics, organ transplant and autoimmune diseases monitoring. To date, he has published 169 peer-reviewed articles with a total citation of over 11,000 and an h-index of 56. He is a co-inventor of over 1,500 patent applications with over 900 granted globally covering 73 inventions on molecular diagnostics. Among his inventions, the noninvasive prenatal test for Down syndrome is the most notable. This test has been adopted in over 70 countries with millions of tests performed each year.

Professor Chan is also an entrepreneur and he co-founded a number of biotechnology companies with Professors Dennis Lo and Rossa Chiu. One of his companies, Cirina, was acquired by GRAIL for over USD 300 million in 2017, and GRAIL was acquired by Illumina, at a cost of over USD 7.1 billion in 2021.

Prof. Mok will lead the SAB and currently serves as Chairman of the Department of Clinical Oncology of Chinese University of Hong Kong, is a non-executive director of AstraZeneca plc, and an independent director of HUTCHMED (China) Limited. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer.

Prof. Mok was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has also led and co-led multiple studies including the FASTACT 2, IMPRESS, ARCHER 1050, ALEX and AURA 3. These projects address various aspects on management of EGFR mutation positive lung cancer, and have played a significant role in defining current practice. Prof. Mok has also engaged in clinical research on ALK positive lung cancer and immunotherapy. The series of clinical trials, led or co-led by Professor Mok, have defined precision medicine. His work has been adopted by multiple international guidelines including NCCN, AMP/IASLC/CAP, ASCO and ESMO.